Morgan Stanley Adjusts Price Target for Evofem Biosciences to $0.75 From $2, Maintains Underweight Rating
Morgan Stanley Adjusts Price Target for Evofem Biosciences to $0.75 From $2, Maintains Underweight Rating
摩根士丹利將Evofem Biosciences的目標股價從2美元調整至0.75美元，維持減持評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊